Immunic, Inc. Common Stock (IMUX)
Immunic, Inc. (IMUX) is a clinical-stage biopharmaceutical company focused on developing oral therapies for autoimmune and inflammatory diseases. The company's pipeline includes immune-modulating treatments aimed at conditions such as multiple sclerosis, ulcerative colitis, and psoriasis. Immunic's approach leverages innovative small molecule compounds designed to target specific pathways involved in immune system regulation.
Company News
The Dow Jones index closed lower by over 20 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable inside...
Immunic (IMUX) reports positive results from the maintenance phase of the phase II study evaluating its lead candidate, vidofludimus calcium, to treat patients with ulcerative colitis.
Hot penny stocks to watch now. The post Best Penny Stocks For 2023? 3 To Watch In March appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.